Elder Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Elder Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Glenmark Pharmaceuticals, SA
Phase I application filed for DPP-IV inhibitor GRC 8200 in U.K.
October 26th, 2005
Glenmark Pharmaceuticals, SA, a wholly owned subsidiary of Glenmark Pharmaceuticals, Ltd., (Glenmark), has filed for phase I clinical trials for GRC 8200, its leading Dipeptidyl peptidase IV (DPP-IV) inhibitor compound, with the Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. The phase I study will be conducted by Parexel U.K., a global contract research organization. The phase I study is expected to be completed in February 2006 and will be conducted using single and multiple oral doses on healthy volunteers. The objective of this study is to assess the safety and bioavailability of GRC 8200 in humans. Preclinical studies have...
Source: Elder Law Weekly (2005-10-26)
|
